English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Jiangsu Hengrui Out-Licenses Novel Dermatology Drug in a $233 Million Deal

Jan. 5, 2018

Jiangsu Hengrui Medicine and Arcutis announced a development and commercialization partnership for novel immune-mediated SHR0302, which is used for the treatment of dermatology disorders. SHR0302, a highly potent, selective JAK inhibitor, is currently being evaluated in phase II clinical trials for rheumatoid arthritis in China.

Hengrui is eligible to receive up to $223 million, including upfront, regulatory and commercial milestone payments, plus royalties.